No need to stop warfarin during vitreoretinal procedures

Article

Cessation of therapy with warfarin may not be necessary in patients receiving anticoagulation who are undergoing vitreoretinal procedures, according to a report in the March issue of Retina.

Cessation of therapy with warfarin may not be necessary in patients receiving anticoagulation who are undergoing vitreoretinal procedures, according to a report in the March issue of Retina.

Arthur D. Fu, MD and colleagues from the California Pacific Medical Center, San Francisco, US, reviewed patient demographics, ocular findings and clinical courses from 25 patients receiving systemic anticoagulation with warfarin who subsequently underwent vitreoretinal surgery. Patients were aged between 49 and 81 years and indications for anticoagulation included atrial fibrillation, cerebrovascular disease, deep vein thrombosis, prosthetic heart valves and hypercoagulable state.

Mean follow-up period was 19.5 months (range 4-36 months) and the international normalized ratio ranged from 1.5 to 3.1. Final vision after surgery raged from 20/20 to 20/400. One patient, undergoing scleral buckling and external driniage of subretinal fluid, had an intraoperative subretinal haemorrhage. No other intraoperative complications occurred.

It was concluded that cessation of therapy with warfarin may not be necessary for patients undergoing vitreoretinal surgery and successful visual and anatomical results can still be achieved.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.